Check out your Company Bowl for anonymous work chats.
Biodesix announced today that it has launched the Biodesix WorkSafe™ Program, a customized return to work service for employers. The program is designed to help all businesses in the U.S. and incorporates two highly-accurate diagnostic tests for COVID-19 with an end-to-end customized solution to assist companies in their goals of preventing and slowing the spread of COVID-19 while resuming business operations. Results for both tests are provided in 24 hours after the sample is received at the Biodesix Laboratory.
Biodesix begins testing for COVID-19 ddPCR™ today. The test reduces false negatives, is collected by the patient’s healthcare provider and provides results in 48-72 hours. The Biodesix lab has capacity for 1,000 COVID-19 tests per day with plans to expand as needs arise.
Biodesix Partners with Bio-Rad to Bring Emergency Use Authorization (EUA) COVID-19 ddPCR™ Test to the U.S.
Our new Nodify CDT test helps determine if a patient with a lung nodule is at high risk of lung cancer. The test is done with a simple blood draw and delivers results in approximately one day.
Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany and Pfizer Inc.
We are proud to have been named Company of the Year by Colorado BioScience Association.
Great spotlight on Abby Wright who oversees the Biodesix Reimbursement department. http://glassdoor.com/slink.htm?key=vMtbB
http://glassdoor.com/slink.htm?key=vMtw1
http://glassdoor.com/slink.htm?key=vMtwp
http://glassdoor.com/slink.htm?key=vMHVo
